Volume 20, Number 11—November 2014
Dispatch
ESBL-Producing Salmonella enterica Serovar Typhi in Traveler Returning from Guatemala to Spain
Anna Fàbrega
, Nuria Piedra-Carrasco, Fernando Salvador, Virginia Rodríguez, Adrián Sánchez-Montalvá, Anna M. Planes, Israel Molina, and M. Nieves Larrosa
, Nuria Piedra-Carrasco, Fernando Salvador, Virginia Rodríguez, Adrián Sánchez-Montalvá, Anna M. Planes, Israel Molina, and M. Nieves Larrosa
Table
Susceptibility profiles of the CTX-M-15–producing Salmonella enterica serovar Typhi strain from a patient in Spain who had traveled to Guatemala in 2013, compared with profiles of the Escherichia coli recipient strain and the transconjugant strain
| Antimicrobial agent(s) | MIC, µg/mL |
||
|---|---|---|---|
| S. enterica ser. Typhi 301812 (donor) | E. coli HB101-Nal (recipient) | E. coli HB101-Nal TC-301812 (transconjugant) | |
| Ampicillin | >256 | 1.5 | >256 |
| Amoxicillin-clavulanate | 16 | 3 | 16 |
| Piperacillin-tazobactam | 3 | 1 | 1.5 |
| Cefoxitin | 12 | 3 | 3 |
| Ceftazidime | >256 | 0.064 | 8 |
| Cefotaxime | >256 | 0.016 | >256 |
| Cefotaxime-clavulanate | 0.19 | 0.016 | 0.016 |
| Cefepime | >256 | 0.032 | 24 |
| Aztreonam | >256 | <0.016 | 32 |
| Imipenem | 0.25 | 0.38 | 0.38 |
| Meropenem | 0.064 | 0.023 | 0.023 |
| Ertapenem | 0.064 | 0.002 | 0.002 |
| Chloramphenicol | 2 | 2 | 2 |
| Trimethoprim-sulfamethoxazole | 0.047 | 0.25 | 0.25 |
| Nalidixic acid | 3 | >256 | >256 |
| Ciprofloxacin | 0.023 | 0.125 | 0.125 |
| Azithromycin | 4 | 3 | 3 |
| Gentamicin | 1.5 | 0.75 | 3 |
| Tobramycin | 24 | 1 | >256 |
| Amikacin | 32 | 2 | >256 |
Page created: October 17, 2014
Page updated: October 17, 2014
Page reviewed: October 17, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.